Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites
Status:
Completed
Trial end date:
2019-12-26
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, parallel-group, open-label study. Forty subjects will be
enrolled and will be randomized into 1 of the 2 treatment groups, with 20 subjects in each
treatment group(sex will be used as a stratifying factor) as follows:
- Treatment Group A (reference): A single oral dose of ozanimod 0.46 mg
- Treatment Group B (test): A single oral dose of ozanimod 0.46 mg plus a single oral dose
of cyclosporine 600 mg